tmem106b Antibody

Introduction to TMEM106B Antibodies

TMEM106B antibodies are immunological reagents specifically designed to recognize and bind transmembrane protein 106B, a lysosomal membrane protein with a molecular weight of approximately 31 kDa . These antibodies serve as essential tools for detecting, quantifying, and examining the localization of TMEM106B in various experimental contexts . Their importance has grown significantly following the discovery that genetic variants in TMEM106B are associated with increased risk for frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP) .

These antibodies are available in multiple formats, including polyclonal, monoclonal, and recombinant variants, targeting different epitopes of the protein. They find applications across a wide spectrum of research techniques including Western blotting, immunohistochemistry, immunofluorescence, and enzyme-linked immunosorbent assays (ELISA) . The recent discovery that TMEM106B forms amyloid fibrils in aging and various neurodegenerative disorders has further elevated the significance of these antibodies in understanding disease mechanisms and developing potential therapeutics .

Gene and Protein Structure

The human TMEM106B gene is located on chromosome 7 at positions 12211270–12243367, spanning approximately 32,097 base pairs and containing 9 exons . This gene encodes a 274-amino acid protein with three distinct domains:

1. N-terminal cytosolic domain

2. Transmembrane domain

3. C-terminal domain containing five N-glycosylation sites in the lysosomal lumen

The protein undergoes proteolytic processing, where proteases cleave TMEM106B to release the C-terminal domain into the lysosomal lumen while creating an N-terminal fragment that remains anchored to the lysosomal membrane . This processing appears critical for the formation of TMEM106B fibrils observed in neurodegenerative conditions.

Physiological Functions

TMEM106B plays several important roles in lysosomal biology:

• Lysosomal size regulation: Overexpression of TMEM106B leads to enlarged lysosomes, triggering cellular stress responses and potentially cell death .

• Lysosomal trafficking: TMEM106B facilitates proper lysosomal movement along microtubules. Knockout studies show inappropriate clustering of lysosomes at the nucleus, while in neurons, TMEM106B loss leads to increased retrograde transport causing accumulation of large lysosomal vacuoles at distal ends of neurons .

• Lysosomal pH maintenance: TMEM106B interacts with vacuolar ATPase (vATPase) accessory proteins, contributing to the maintenance of the acidic lysosomal environment (pH 4.5-5) .

TMEM106B Fibrils in Disease

A significant discovery is that TMEM106B can form amyloid fibrils in various neurodegenerative diseases and even in neurologically healthy aging individuals . These fibrils have been structurally characterized by cryo-electron microscopy and consist of either single rod-like structures or doublets of filaments forming twisted ribbons . The fibrils are primarily composed of a 135-amino acid portion from the protein's C-terminal domain and represent an important focus of current research in relation to frontotemporal dementia and other TDP-43 proteinopathies .

Polyclonal Antibodies

Polyclonal TMEM106B antibodies are produced by immunizing animals (typically rabbits) with TMEM106B-derived peptides or recombinant proteins. These antibodies recognize multiple epitopes on the TMEM106B protein, offering high sensitivity but potentially lower specificity compared to monoclonal antibodies . Examples include Proteintech's TMEM106B polyclonal antibody (20995-1-AP) and Boster's Anti-TMEM106B antibody (A03541) .

Monoclonal Antibodies

Monoclonal TMEM106B antibodies derive from single B-cell clones and recognize specific epitopes with high specificity. These antibodies offer consistent performance across batches and are particularly useful for applications requiring high specificity . An example is Abcam's Anti-TMEM106B antibody [EPR27525-70] (ab321970) .

Recombinant Antibodies

Recombinant TMEM106B antibodies are engineered using recombinant DNA technology, offering advantages in consistency, specificity, and reduced batch-to-batch variation . Examples include Proteintech's TMEM106B recombinant antibodies (84196-2-RR and 84196-1-RR) .

By Target Epitope

TMEM106B antibodies target different regions of the protein, significantly impacting their utility in various applications:

Different epitope targets are particularly important when studying specific aspects of TMEM106B biology. For instance, antibodies targeting the C-terminal fragments (188-211aa and 239-250aa) have demonstrated utility in detecting TMEM106B-immunoreactive material in brain tissue samples .

By Host Species and Reactivity

TMEM106B antibodies are produced in various host species and show reactivity with different target species:

Understanding the reactivity profile is crucial for experimental design, particularly for cross-species studies or when working with animal models of disease.

Immunogen Selection and Preparation

For TMEM106B antibodies, immunogens typically consist of:

1. Synthetic peptides: Corresponding to specific regions of TMEM106B, such as residues 188-211 or 239-250 .

2. Fusion proteins: Recombinant TMEM106B fragments expressed with fusion tags to enhance immunogenicity, as with Proteintech's 20995-1-AP antibody using TMEM106B (150-274aa) fusion protein .

3. Recombinant protein fragments: Expression of specific domains of TMEM106B in bacterial or mammalian expression systems.

Antibody Production Process

For polyclonal antibodies, the typical process involves:

1. Immunizing rabbits with the selected immunogen, often conjugated to a carrier protein such as keyhole limpet hemocyanin (KLH).

2. Administering multiple booster injections over several weeks to enhance the immune response.

3. Collecting serum and purifying antibodies through affinity chromatography.

For monoclonal or recombinant antibodies, additional steps include:

1. Isolation of B cells from immunized animals.

2. Fusion with myeloma cells to create hybridomas (for monoclonals) or cloning of antibody genes (for recombinants).

3. Selection and expansion of clones producing antibodies with desired characteristics.

4. Large-scale production and purification.

Purification and Quality Control

Purification methods typically include:

1. Antigen affinity purification: The most common method, where antibodies are purified based on their ability to bind to immobilized TMEM106B antigens .

2. Protein A/G purification: Used for IgG antibodies, especially for recombinant antibodies .

Quality control steps include validation of specificity using knockout cell lines, ELISA testing to confirm binding to the target epitope, and application-specific validations such as Western blot, immunohistochemistry, or immunofluorescence .

Western Blotting

Western blotting represents one of the most common applications, allowing for detection and semi-quantification of TMEM106B in cell and tissue lysates. Key considerations include:

• Molecular weight detection: TMEM106B is typically observed between 31-55 kDa, with variations due to glycosylation and other post-translational modifications. Some antibodies also detect higher molecular weight forms (70-90 kDa) representing glycosylated or dimeric forms .

• Recommended dilutions: Vary widely between antibodies, as shown below:

Immunohistochemistry and Immunofluorescence

TMEM106B antibodies are widely used for immunohistochemistry (IHC) and immunofluorescence (IF) to investigate cellular and subcellular localization:

• Tissue localization: TMEM106B is highly expressed in the central nervous system, particularly in neurons and oligodendrocytes. In normal brain tissue, TMEM106B antibodies typically reveal cytoplasmic staining patterns consistent with lysosomal localization .

• Pathological structures: Specialized antibodies targeting specific epitopes (e.g., residues 188-211 or 239-250) can detect TMEM106B-immunoreactive material in aging brains and various neurodegenerative diseases .

Recommended dilutions for IHC/IF applications vary by antibody:

Additional Applications

TMEM106B antibodies have been validated for several other applications:

• ELISA: For quantitative measurement of TMEM106B levels in biological samples .

• Immunoprecipitation: For isolation of TMEM106B and associated protein complexes, valuable for studying protein-protein interactions .

• Flow Cytometry: For analysis of TMEM106B expression at the single-cell level, such as with MyBioSource's MBS9231053 antibody validated at a 1:25 dilution .

Major Suppliers and Products

A wide range of TMEM106B antibodies is commercially available from various suppliers:

According to the search results, Biocompare lists 158 TMEM106B antibodies across 23 suppliers, indicating wide commercial availability .

Selection Criteria

When selecting a TMEM106B antibody for research, several key factors should be considered:

1. Target application: Different antibodies perform optimally in specific applications. Studies have characterized commercial antibodies for Western blot, immunoprecipitation, and immunofluorescence applications .

2. Epitope specificity: Depending on the research question, antibodies targeting different regions may be preferable. For instance, antibodies targeting the C-terminal region have shown utility in detecting TMEM106B fibrils in brain tissue .

3. Validation data: The availability of comprehensive validation data, including knockout controls, is critical for ensuring antibody specificity .

4. Species reactivity: The antibody's reactivity with the species being studied is crucial. Many TMEM106B antibodies show reactivity with both human and mouse samples, though some are species-specific .

5. Publication record: Antibodies with a track record in peer-reviewed publications provide additional confidence in their performance and reliability .

Validation Approaches

Several approaches are used to validate TMEM106B antibodies:

1. Knockout validation: Using TMEM106B knockout cell lines to confirm antibody specificity. This approach provides the strongest evidence for specificity, as demonstrated with antibodies like Abcam's ab321970 .

2. Peptide competition: Demonstrating that pre-incubation with the immunizing peptide blocks antibody binding, as shown with Boster's A03541 antibody .

3. Cross-reactivity assessment: Testing reactivity against closely related proteins, such as TMEM106A and TMEM106C, to confirm specificity .

4. Multiple antibody concordance: Comparing staining patterns obtained with antibodies targeting different epitopes of TMEM106B .

Performance in Different Applications

A study described in search result characterized six commercially available TMEM106B antibodies for their performance in Western blot, immunoprecipitation, and immunofluorescence applications using standardized protocols. The study compared results in knockout cell lines and isogenic parental controls to identify high-performing antibodies for each application .

Key findings from validation studies include:

• Variability in antibody performance across different applications, with some antibodies performing well in multiple applications while others show application-specific utility.

• The importance of thorough validation, particularly for studies of TMEM106B in neurodegenerative diseases where accurate detection is critical.

• The value of comparing multiple antibodies targeting different epitopes to confirm findings and enhance confidence in results.

Frontotemporal Lobar Degeneration (FTLD)

TMEM106B antibodies have revealed several key findings in FTLD research:

• The presence of TMEM106B fibrils in FTLD-TDP patient brains, detectable using specific antibodies targeting the C-terminal domain .

• An association between the TMEM106B rs3173615 risk allele and increased TMEM106B core accumulation in FTLD-TDP patients, correlating with enhanced TDP-43 dysfunction .

• A protective effect of the TMEM106B rs3173615 protective genotype, associated with longer survival after symptom onset and minimal TMEM106B core deposition .

These findings suggest that TMEM106B antibodies could potentially serve as valuable tools for studying disease mechanisms and as diagnostic markers for FTLD-TDP.

Alzheimer's Disease

Studies using TMEM106B antibodies have investigated the protein's role in Alzheimer's disease:

• Research has shown that TMEM106B mRNA and protein levels are significantly reduced in AD brains compared to non-AD brains, while progranulin (PGRN) mRNA levels are elevated .

• Immunohistochemistry studies have revealed that surviving neurons in AD brains express intense TMEM106B immunoreactivity, while senile plaques, neurofibrillary tangles, and perivascular neuropil show minimal TMEM106B expression but strong PGRN expression .

Other Neurodegenerative Diseases

TMEM106B antibodies have been used to study the protein's role in other neurodegenerative conditions:

• Detection of TMEM106B fibrils in progressive supranuclear palsy and dementia with Lewy bodies, suggesting a broader role for TMEM106B aggregation across multiple neurodegenerative diseases .

• Investigation of TMEM106B expression and localization in amyotrophic lateral sclerosis (ALS), a condition that, like FTLD-TDP, is characterized by TDP-43 inclusions .

Patent Developments

A patent filed by Alector Inc. (US20230303681A1) describes antibodies targeting TMEM106B for treating various conditions:

• The patent claims isolated nucleic acids encoding antibodies with specific amino acid sequences targeting TMEM106B .

• The patent covers methods of preventing, reducing risk, or treating various diseases by administering these antibodies, including neurodegenerative disorders, FTLD, frontotemporal dementia, Alzheimer's disease, and Lewy body dementia .

• The patent describes modifications to facilitate transport across the blood-brain barrier, including targeting transferrin receptor, insulin receptor, or using protein transduction domains .

Potential Therapeutic Mechanisms

Several mechanisms have been proposed through which TMEM106B antibodies might exert therapeutic effects:

1. Targeting TMEM106B fibrils: Antibodies specifically targeting the core region of TMEM106B fibrils could potentially reduce fibril accumulation, which has been associated with disease progression in FTLD-TDP .

2. Modulating lysosomal function: By targeting TMEM106B, antibodies might help restore normal lysosomal size, trafficking, and pH, addressing fundamental cellular dysfunctions in neurodegenerative diseases .

3. Reducing TDP-43 dysfunction: Given the association between TMEM106B accumulation and enhanced TDP-43 dysfunction, antibodies targeting TMEM106B might indirectly ameliorate TDP-43-related pathology .

Future Directions in TMEM106B Antibody Research

Research on TMEM106B antibodies continues to evolve, with several promising directions:

1. Development of aggregate-specific antibodies: Further refinement of antibodies specifically targeting TMEM106B fibril structures could enhance detection of pathological aggregates and potentially lead to therapeutic applications .

2. Biomarker development: Investigation of TMEM106B antibodies for diagnostic or prognostic applications in neurodegenerative diseases, particularly in identifying individuals at risk for rapid disease progression .

3. Mechanistic studies: Use of increasingly specific TMEM106B antibodies to elucidate the precise mechanisms by which TMEM106B contributes to disease pathogenesis, including its interactions with TDP-43 and progranulin .

4. Therapeutic antibody optimization: Refinement of therapeutic antibodies targeting TMEM106B, including optimization of blood-brain barrier penetration and specific targeting of pathological forms while sparing physiological TMEM106B function .

5. Standardized protocols: Establishment of standardized validation protocols and benchmarking for TMEM106B antibodies to enhance reliability and reproducibility across research studies .